Skip to main content

Table 2 Multivariable-adjusted odds ratios of potential risk factors for low DLCO

From: The association between transfer coefficient of the lung and the risk of exacerbation in asthma-COPD overlap: an observational cohort study

Variables

Number of events/cases (%)

Multivariable-adjusted OR (95% CI)

P value

 

Exposure group

Reference group

  

Male gender

21/77 (27.3%)

8/17 (47.3%)

0.90 (0.18–4.40)

0.89

Age (per 10-year increase)

N/A

N/A

0.83 (0.41–1.66)

0.60

BMI (per 1 kg/m2 increase)

N/A

N/A

1.03 (0.86–1.22)

0.76

FEV1 (per 1 L increase)

N/A

N/A

0.29 (0.10–0.76)

0.02

Inhaled long-acting bronchodilator use

22/68 (32.4%)

7/26 (26.9%)

8.42 (0.93–108)

0.07

ICS use

17/64 (26.6%)

12/30 (40.0%)

0.07 (0.01–0.59)

0.02

COPD-like features

    

Smoking history ≥ 10 pack-years

28/87 (32.2%)

1/7 (14.3%)

3.32 (0.34–80.7)

0.36

Emphysema

22/64 (34.4%)

7/30 (23.3%)

1.32 (0.39–4.77)

0.66

Asthmatic features

    

Eosinophilic component

18/56 (32.1%)

11/38 (28.9%)

1.65 (0.51–5.71)

0.41

High FeNO

11/44 (25.0%)

18/50 (36.0%)

0.51 (0.15–1.61)

0.26

Positive levels for total IgE and/or IgE specific to perennial inhalant antigens

21/75 (28.0%)

8/19 (42.1%)

0.51 (0.12–2.06)

0.34

Bronchial reversibility

5/18 (27.8%)

24/76 (31.6%)

1.08 (0.24–4.20)

0.92

  1. Adjustment was made for age, gender, BMI, FEV1, long-acting bronchodilator use, ICS use, a smoking history of > 10 pack-years, emphysema, high FeNO, bronchial reversibility, an eosinophilic component, and positive levels for total IgE and/or IgE specific to perennial inhalant antigens. The eosinophilic component was defined as blood eosinophil ≥ 5% and/or ≥ 300/µl. High FeNO was defined as ≥ 35 parts per billion. Bronchial reversibility was defined as ≥ 12% and ≥ 200 ml reversibility in post-bronchodilator FEV1. Positive levels for total IgE were defined as > 170 IU/ml
  2. OR, odds ratio; 95% CI, 95% confidence interval; BMI, body mass index; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; COPD, chronic obstructive pulmonary disease; N/A, not applicable